Clinical Trial Detail

NCT ID NCT02305186
Title Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Osama Rahma, MD
Indications

pancreatic cancer

Therapies

Pembrolizumab

Capecitabine

Age Groups: adult

No variant requirements are available.